INO Inovio Pharmaceuticals Inc: חובות לטווח קצר של החברה

This daily price chart for Inovio Pharmaceuticals (INO) reflects the performance of the company developing antiviral protections, where the specific short-term debt metric stands at 0.00. Business profitability relies on the implementation of genetic drugs in hospitals, with calculations based on regular payments from insurance funds. Meanwhile, a neutral political backdrop ensures seamless logistics and the execution of global trials.

The complex certification cycles for Inovio Pharmaceuticals (INO) DNA drugs require colossal expenditures for long-term research. This indicator aggregates all of the issuer's credit obligations with a maturity of up to one year. An increase in this metric signals a risk of cash flow gaps in the event of insufficient liquidity inflows. It is critical for investors to compare these liabilities with the cost of capital to assess financial stability. Analyzing the history of short-term liabilities allows for the determination of the company's dependence on rapid refinancing.